Menu

Avid Bioservices Q2 loss narrows despite lower revenues; reaffirms outlook

By Staff Correspondent |

Avid Bioservices (CDMO) reported a narrower net loss for the second quarter of 2019, helped by a sharp decline in costs. Revenues, meanwhile, declined and missed estimates. The company also reaffirmed its full-year revenue guidance.

Net loss narrowed to $2.89 million or $0.05 per share from $14.07 million or $0.31 per share in the second quarter of 2018. Analysts had forecast a wider loss. During the quarter, manufacturing cost declined 40% to $9.8 million.

Revenues of the Tustin, California-based biotech contract manufacturer dropped 20% year-on-year to $10.18 million and fell short of expectations. The top line performance was dragged by maintenance shutdowns of manufacturing facilities and a decline in demand from two lead customers.

The top line performance was dragged by maintenance shutdowns of manufacturing facilities and a decline in demand from two lead customers

The management also reaffirmed its full-year 2019 revenue outlook in the range of $51 million to $55 million, encouraged by the progress in the implementation of various turnaround initiatives that helped the company move closer to achieving optimum capacity utilization and cash flow.

“Collectively our significant operational and commercial progress, along with diligent management of our financial resources position Avid Bioservices well for transition to cash generation and positive EBITDA,” said CEO Roger Lias. Echoing Lias’ views, market watchers had forecast that the company’s top-line will bounce back, in the long run, helped by its turnaround initiatives and new contract wins.

Moderna raises over $600-million through IPO, falls below IPO price

Avid Bioservices received mixed ratings from analysts in the recent weeks, with the majority recommending buy and setting a price target of $8.33. The healthcare contract manufacturing sector stands to benefit from the growing demand for medical devices and pharmaceutical products, including generic drugs.

The company’s shares have declined about 35% in the past twelve months.  The stock closed Monday’s trading session up 1%.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference, and much more!

Advertisement

238 responses to “Avid Bioservices Q2 loss narrows despite lower revenues; reaffirms outlook”

  1. Dental technology

    […]Wonderful story, reckoned we could combine several unrelated data, nevertheless definitely worth taking a search, whoa did 1 find out about Mid East has got far more problerms at the same time […]

  2. FiverrEarn

    […]Wonderful story, reckoned we could combine some unrelated information, nevertheless actually really worth taking a appear, whoa did one understand about Mid East has got a lot more problerms at the same time […]

  3. nangs near me

    […]Wonderful story, reckoned we could combine a handful of unrelated information, nevertheless seriously really worth taking a look, whoa did a single study about Mid East has got extra problerms too […]

  4. หวย24

    […]Wonderful story, reckoned we could combine some unrelated information, nonetheless seriously really worth taking a search, whoa did 1 discover about Mid East has got extra problerms also […]

  5. cam sex

    […]although web sites we backlink to below are considerably not connected to ours, we really feel they may be basically really worth a go as a result of, so possess a look[…]

  6. clima en chimalhuacan

    […]Wonderful story, reckoned we could combine a few unrelated information, nonetheless seriously really worth taking a appear, whoa did a single discover about Mid East has got additional problerms at the same time […]

  7. esports

    […]we like to honor several other online web-sites on the internet, even if they aren’t linked to us, by linking to them. Beneath are some webpages really worth checking out[…]

Leave a Reply

Top